HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017 – GlobeNewswire (press release)
|
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
GlobeNewswire (press release) For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin lymphoma (NHL) patients has been described. Data analysis pointed to immune programs which may facilitate or modulate anti-tumor … |
